The Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) drugs in development market research report provides comprehensive information on the therapeutics under development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) by 11 companies/universities/institutes. The top development phase for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) is preclinical with six drugs in that stage. The Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline products market are: Daiichi Sankyo, Quoin Pharmaceuticals and Matrisys Bioscience.
The key targets in the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline products market include Kallikrein 5, Serine Protease Inhibitor Kazal Type 5, and Kallikrein 7.
The key mechanisms of action in the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline product include Kallikrein 5 Inhibitor with four drugs in Phase II. The Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline products include six routes of administration with the top ROA being Topical and six key molecule types in the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline products market including Biologic, and Gene Therapy.
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) overview
Netherton syndrome is a rare disorder affecting the skin, hair, and immune system. It is a severe, autosomal recessive form of ichthyosis associated with mutations in the SPINK5 gene, which encodes the serine protease inhibitor lympho-epithelial Kazal-type-related inhibitor (LEKTI). These mutations result in a dysfunctional protein that has a reduced capacity to inhibit serine proteases expressed in the skin. Symptoms are present at birth and include red, scaly skin. Other symptoms include outbreaks of red, circular scaly rashes; thin, fragile hair (bamboo hair); and immune reactions such as hay fever, asthma, itchy skin, and eczema.
For a complete picture of Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
